Versantis is a clinical-stage pharmaceutical company that aims to revolutionize the care of patients with liver and rare pediatric diseases. Founded in 2015, the company's mission is to provide multiorgan support for rare pediatric and acute liver diseases. Versantis has recently received a significant investment of Fr.475.00K in the form of a grant from Innosuisse, indicating a strong interest in the company's innovative approach. The company focuses on addressing unmet medical needs in emergency care, particularly aiming to support acute decompensations of cirrhosis and save infants born with rare genetic disorders. Versantis operates within the health care and pharmaceutical industries, positioning itself as a key player in advancing treatment options for these critical medical conditions.
Versantis
Multiorgan support for rare pediatric and acute liver diseases
Zurich, Switzerland
2 employees
Grant
Total: $21.11M
Health Care, Health and Wellness +1
General Information
Get notified when Versantis moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Track Versantis
Get real-time alerts for funding, hiring, news, and 40+ signal types.
Start Tracking — FreeDiscover More
Switzerland Market
Health Care
About Versantis
Taxonomy: Pharmaceutical company, Orphan medicines, Liver diseases, Rare pediatric diseases, Acute liver disease, Clinical-stage, Emergency care, Multiorgan support, Genetic disorders, Preventive therapies, Rare indications, Drug development, Orphan Drug Designation, Swiss pharmaceutical company
Funding Rounds & Investors (8)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Grant | •••••• | 1 |
|
13 Apr 2022 |
| Series B | •••••• | 6 |
|
18 Sep 2019 |
| Series A | •••••• | 6 |
|
29 Mar 2017 |
| Non Equity Assistance | •••••• | 1 |
|
02 Nov 2016 |
| Seed Round | •••••• | 1 |
|
21 Jan 2015 |
Versantis Alternatives & Competitors
Pioneering breakthroughs in genetic disorders and liver diseases using RNA interference technology.
Ultragenyx is a biopharmaceutical company focused on developing therapies for rare and very rare dis...
Creating the Trusted Path to a Fulfilled Life for Patients with Orphan, Ultra-Orphan, and Rare Disea...
FAQ About Versantis
Don't just browse. Track.
Signal Tracker monitors Versantis and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.